Please login to the form below

Not currently logged in
Email:
Password:

Virginia Acha leaves Amgen for ABPI

Joins UK pharma trade body as director of research, medical and innovation

ABPI, Virginia AchaTrade body the Association of the British Pharmaceutical Industry (ABPI) has appointed Amgen director Virginia (Ginny) Acha as executive director in charge of research, medical and innovation.

Dr Acha is currently director of global regulatory and R&D policy across the EMEA region for Amgen, a role she has held for two years after joining the company from Pfizer.

She spent five years at Pfizer including periods as government affairs manager in the UK and director of international policy.

Dr Acha will take up her position at the ABPI in March at what will be a key time for the UK life sciences industry with the general election set to take place in May.

“These are exciting times in the science, development and delivery of medicines, and so it is a great privilege to be joining the ABPI now to help deliver our industry's views and aspirations for the future of healthcare,” she said.

In addition to her experience in the pharma industry Dr Acha has had an extensive career in academia holding posts at Imperial College London Business School, the Science Policy Research Unit (SPRU) at the University of Sussex and the Centre for Research in Innovation Management (CENTRIM) at the University of Brighton.

She is currently a visiting researcher in the innovation and entrepreneurship department at Imperial College Business School London.

27th January 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics